XIE Hua
Principal Investigator
Cancer Research Center
Personal Homepage
CONTACT
hxie@simm.ac.cn
021-50805897
201203
555 Zu Chong Zhi Road, Zhang Jiang Hi-Tech Park, Pudong, Shanghai, P.R.China
Biography
Dr. Hua Xie is a professor and principal investigator of Shanghai Institute of Materia Medica. Her research mainly focuses on discovery and development of innovative anticancer drugs. She has played a leading role in the development of three novel drug candidates. ASK120067 that targets EGFR T790M mutations for non-small cell lung cancer is undergoing phase III clinical trial in China. She has published more than 60 research articles in peer-review journals including prestigious international journals in the fields of tumor pharmacology and oncology, such as Molecular Cancer and Cancer Research.
Education
1.2001.09-2004.07 Zhengzhou University, Ph.D. in Medicine
2.1996.09-1999.07 Zhengzhou University, M.A. in Pharmacology
3.1989.09-1994.07 Zhengzhou University, B.S. in Clinical Medicine
Work Experience
1.2020.03-now Shanghai Institute of Materia Medica, Principal Investigator, Professor
2.2013.09-2020.01 Shanghai Institute of Materia Medica, Professor
3.2011.01-2012.06 Hormel Institute, University of Minnesota, Postdoctoral fellow
4.2004.08-2013.08 Shanghai Institute of Materia Medica, Postdoctoral fellow, Assistant Professor, Associate Professor
5.1994.08-2004.07 Zhengzhou University，Assistant, Lecturer
Research Directions
1.Discovery and development of molecularly targeted anticancer drugs;
2.Exploring molecular mechanisms and biomarkers of anticancer drugs;
3.Discovery of molecular basis of drug resistance.
Grants & Research Projects
1.2009, 2019 National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”
2.2015, 2017, 2019 Strategic Priority Research Program of the Chinese Academy of Sciences
3.2012 National Natural Sciences fund
Achievements
1.Three anticancer drug candidates entered into clinical trials.
2.Hold 19 domestic or international patents.
3.Pulished more than 60 research articles in SCI-sited journals.
morefold
Social Titles
morefold
Awards & Honors
morefold
Pubilcations
Full Publication List
Selected Publications
1. T Zhang#, R Qu#, SP Chan#, MZ Lai, LJ Tong, F Feng, HY Chen, TT Song, PR Song, G Bai, YQ Liu, YN Wang, Y Li, Y Su, YY Shen, YM Sun, Y Chen, MY Geng, K Ding*, J Ding*, H Xie*. Discovery of a novel third- generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020 May 13;19(1):90.
2. MZ Lai#, PR Song#, D Dou#, YY Diao, LJ Tong, T Zhang, H Xie*, HL Li*, J Ding*. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl) phenyl)amino)-4-methyl-2- oxo-2Hpyrimido[4,5-d][1,3]oxazin-1(4H)-ly)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors. Acta Pharm Sin. 2020 Mar;41(3):415-422.
3. Z Chen#, LJ Tong, BY Tang, HY Liu, X Wang, T Zhang, XW Cao, Y Chen, HL Li, XH Qian, YF Xu*, H Xie*, J Ding*. C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharma Sin. 2019 Jun;40(6):823-832.
4. H Xie#, MH Lee#, F Zhu#, K Reddy#, C Peng, Y Li, DY Lim, DJ Kim, X Li, S Kang, HT Li, WY Ma, RA Lubet, J Ding, AM Bode, ZG Dong*. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res. 2013 Jan 15;73(2):716-724.
5. H Xie#, MH Lee#, F Zhu#, Reddy K, ZN Huang, DJ Kim, Y Li, C Peng, DY Lim, S Kang, SK Jung, X Li, HT Li, WY Ma, RA Lubet, J Ding, AM Bode, ZG Dong*. Discovery of the novel mTOR inhibitor and its antitumor activities in vitro and in vivo. Mol Cancer Thera. 2013 Jun;12(6):950-958.
morefold
Back